Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

ElevateBio

4 Disclosed Funding Rounds $845,000,000

0 Participating Investments


Therapeutics, Health Care, Genetics, Biotechnology

ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.

Cambridge, Massachusetts, United States, North America (US)

Organizations in Cambridge in Therapeutics,
Organizations in Cambridge in Health Care,
Organizations in Cambridge in Genetics,
Organizations in Cambridge in Biotechnology,
Organizations in Massachusetts in Therapeutics,
Organizations in Massachusetts in Health Care,
Organizations in Massachusetts in Genetics,
Organizations in Massachusetts in Biotechnology,
Organizations in United States in Therapeutics,
Organizations in United States in Health Care,
Organizations in United States in Genetics,
Organizations in United States in Biotechnology,
Organizations in North America in Therapeutics,
Organizations in North America in Health Care,
Organizations in North America in Genetics,
Organizations in North America in Biotechnology

Investors in Cambridge in Therapeutics,
Investors in Cambridge in Health Care,
Investors in Cambridge in Genetics,
Investors in Cambridge in Biotechnology,
Investors in Massachusetts in Therapeutics,
Investors in Massachusetts in Health Care,
Investors in Massachusetts in Genetics,
Investors in Massachusetts in Biotechnology,
Investors in United States in Therapeutics,
Investors in United States in Health Care,
Investors in United States in Genetics,
Investors in United States in Biotechnology,
Investors in North America in Therapeutics,
Investors in North America in Health Care,
Investors in North America in Genetics,
Investors in North America in Biotechnology

Greater Boston Area (0 Investors) (0 Startups), New England (0 Investors) (0 Startups), East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups)

Founded date 01, 2017

Founders Mitchell Finer, Vikas Sinha, David Hallal

Operating Status Active

Funding Stage Late Stage Venture

Last Funding Type Series C

Company Type For Profit


Twitter Link

LinkedIN Link

Wikipedia Link

ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's most innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.

Date Round Raised Lead
March, 15, 2021 Series C $525,000,000 Matrix Capital Management
March, 30, 2020 Series B $170,000,000 Vestinwolf Alternatives
May, 13, 2019 Series A $150,000,000 UBS Oncology Impact Fund
January, 01, 2018 Series A Undisclosed -------

ElevateBio Investors (29)

Investor Lead? Round Participating Raise Date Partners
Matrix Capital Management Yes Series C $525,000,000 March, 15, 2021 -------
EDBI No Series C $525,000,000 March, 15, 2021 -------
Emerson Collective No Series C $525,000,000 March, 15, 2021 -------
Samsara BioCapital No Series C $525,000,000 March, 15, 2021 -------
Surveyor Capital No Series C $525,000,000 March, 15, 2021 -------
ITOCHU Corporation No Series C $525,000,000 March, 15, 2021 -------
Redmile Group No Series C $525,000,000 March, 15, 2021 -------
Vertex Ventures No Series C $525,000,000 March, 15, 2021 -------
Fidelity Management and Research Company No Series C $525,000,000 March, 15, 2021 -------
Invus No Series C $525,000,000 March, 15, 2021 -------
F2 Ventures No Series C $525,000,000 March, 15, 2021 -------
SoftBank Vision Fund No Series C $525,000,000 March, 15, 2021 -------
MPM Capital No Series C $525,000,000 March, 15, 2021 -------
EcoR1 Capital No Series C $525,000,000 March, 15, 2021 -------
Surveyor Capital No Series B $170,000,000 March, 30, 2020 -------
Vertex Ventures No Series B $170,000,000 March, 30, 2020 -------
EcoR1 Capital No Series B $170,000,000 March, 30, 2020 -------
MPM Capital No Series B $170,000,000 March, 30, 2020 -------
Redmile Group No Series B $170,000,000 March, 30, 2020 -------
F2 Ventures No Series B $170,000,000 March, 30, 2020 -------
Invus No Series B $170,000,000 March, 30, 2020 -------
Samsara BioCapital No Series B $170,000,000 March, 30, 2020 -------
EDBI No Series B $170,000,000 March, 30, 2020 -------
Vestinwolf Alternatives Yes Series B $170,000,000 March, 30, 2020 -------
Redmile Group No Series A $150,000,000 May, 13, 2019 -------
EcoR1 Capital No Series A $150,000,000 May, 13, 2019 -------
Samsara BioCapital No Series A $150,000,000 May, 13, 2019 -------
UBS Oncology Impact Fund Yes Series A $150,000,000 May, 13, 2019 -------
Sebastien Breteau No Series A Undisclosed January, 01, 2018 -------